Bicycle Therapeutics plc

NasdaqGS:BCYC Stock Report

Mkt Cap: US$829.2m

We’ve recently updated our valuation analysis.

Bicycle Therapeutics Valuation

Is BCYC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BCYC?

Other financial metrics that can be useful for relative valuation.

BCYC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue34x
Enterprise Value/EBITDA-5.1x
PEG Ration/a

Price to Book Ratio vs Peers

How does BCYC's PB Ratio compare to its peers?

The above table shows the PB ratio for BCYC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average4.6x
ICPT Intercept Pharmaceuticals
7.1x44.8%US$760.8m
EBS Emergent BioSolutions
0.5x64.2%US$654.5m
MRUS Merus
2.3x65.7%US$683.0m
ARDX Ardelyx
8.7x62.0%US$581.8m
BCYC Bicycle Therapeutics
2.9x1.9%US$829.2m

Price-To-Book vs Peers: BCYC is good value based on its Price-To-Book Ratio (2.9x) compared to the peer average (4.6x).


Price to Earnings Ratio vs Industry

How does BCYC's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.0%
n/an/an/a

Price-To-Book vs Industry: BCYC is expensive based on its Price-To-Book Ratio (2.9x) compared to the US Biotechs industry average (1.8x)


Price to Book Ratio vs Fair Ratio

What is BCYC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BCYC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate BCYC's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of BCYC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BCYC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BCYC's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BCYC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$28.00
US$53.64
+91.6%
21.4%US$74.00US$33.00n/a14
Jan ’24US$29.60
US$53.54
+80.9%
22.3%US$74.00US$33.00n/a13
Dec ’23US$28.89
US$53.71
+85.9%
23.4%US$74.00US$33.00n/a14
Nov ’23US$25.78
US$54.64
+112.0%
25.2%US$74.00US$33.00n/a14
Oct ’23US$23.26
US$54.64
+134.9%
25.2%US$74.00US$33.00n/a14
Sep ’23US$26.25
US$55.00
+109.5%
26.5%US$74.00US$30.00n/a14
Aug ’23US$22.68
US$57.86
+155.1%
27.5%US$80.00US$30.00n/a14
Jul ’23US$17.49
US$60.23
+244.4%
24.3%US$80.00US$33.00n/a13
Jun ’23US$15.25
US$62.38
+309.1%
20.6%US$80.00US$33.00n/a13
May ’23US$23.48
US$65.85
+180.4%
17.0%US$80.00US$33.00n/a13
Apr ’23US$43.44
US$70.38
+62.0%
15.5%US$100.00US$60.00n/a13
Mar ’23US$47.30
US$71.54
+51.2%
16.2%US$100.00US$60.00n/a13
Feb ’23US$49.54
US$73.33
+48.0%
15.1%US$100.00US$60.00n/a12
Jan ’23US$60.87
US$73.33
+20.5%
15.1%US$100.00US$60.00US$29.6012
Dec ’22US$56.67
US$72.50
+27.9%
15.9%US$100.00US$60.00US$28.8910
Nov ’22US$53.50
US$72.50
+35.5%
15.9%US$100.00US$60.00US$25.7810
Oct ’22US$44.52
US$45.80
+2.9%
15.9%US$58.00US$35.00US$23.2610
Sep ’22US$37.81
US$44.67
+18.1%
15.2%US$58.00US$35.00US$26.259
Aug ’22US$31.60
US$44.67
+41.4%
15.2%US$58.00US$35.00US$22.689
Jul ’22US$31.02
US$41.33
+33.2%
21.2%US$58.00US$30.00US$17.499
Jun ’22US$29.77
US$41.33
+38.8%
21.2%US$58.00US$30.00US$15.259
May ’22US$31.00
US$38.56
+24.4%
25.2%US$58.00US$30.00US$23.489
Apr ’22US$30.48
US$36.75
+20.6%
23.8%US$58.00US$30.00US$43.448
Mar ’22US$25.67
US$34.88
+35.9%
27.1%US$58.00US$25.00US$47.308
Feb ’22US$26.93
US$34.88
+29.5%
27.1%US$58.00US$25.00US$49.548
Jan ’22US$17.95
US$27.75
+54.6%
13.5%US$35.00US$22.00US$60.878

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies